vs
Side-by-side financial comparison of CF BANKSHARES INC. (CFBK) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $15.7M, roughly 1.0× CF BANKSHARES INC.). CF BANKSHARES INC. runs the higher net margin — 40.0% vs -7.8%, a 47.8% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 12.6%). Over the past eight quarters, CF BANKSHARES INC.'s revenue compounded faster (13.7% CAGR vs 11.0%).
CF Bankshares Inc. is a U.S.-based regional bank holding company operating through its community bank subsidiary. It offers a full suite of personal and commercial banking solutions including deposit products, various loan options, wealth management services and digital banking tools, primarily serving individual consumers and small-to-medium business clients across the U.S. Midwest region.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
CFBK vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.7M | $16.1M |
| Net Profit | $5.7M | $-1.2M |
| Gross Margin | — | — |
| Operating Margin | 43.4% | -2.8% |
| Net Margin | 40.0% | -7.8% |
| Revenue YoY | 12.6% | 27.3% |
| Net Profit YoY | 29.9% | -182.0% |
| EPS (diluted) | $0.88 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.7M | $16.1M | ||
| Q3 25 | $15.5M | $17.0M | ||
| Q2 25 | $15.6M | $15.0M | ||
| Q1 25 | $14.1M | $13.1M | ||
| Q4 24 | $14.0M | $12.6M | ||
| Q3 24 | $13.1M | $14.6M | ||
| Q2 24 | $12.6M | $14.9M | ||
| Q1 24 | $12.2M | $13.0M |
| Q4 25 | $5.7M | $-1.2M | ||
| Q3 25 | $2.3M | $-2.3M | ||
| Q2 25 | $5.0M | $-3.8M | ||
| Q1 25 | $4.4M | $-4.1M | ||
| Q4 24 | $4.4M | $1.5M | ||
| Q3 24 | $4.2M | $-2.4M | ||
| Q2 24 | $1.7M | $-3.4M | ||
| Q1 24 | $3.1M | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | 43.4% | -2.8% | ||
| Q3 25 | 17.5% | -9.0% | ||
| Q2 25 | 41.1% | -19.2% | ||
| Q1 25 | 39.5% | -25.3% | ||
| Q4 24 | 36.9% | 17.7% | ||
| Q3 24 | 40.4% | -19.8% | ||
| Q2 24 | 15.4% | -19.7% | ||
| Q1 24 | 30.9% | -77.4% |
| Q4 25 | 40.0% | -7.8% | ||
| Q3 25 | 15.1% | -13.6% | ||
| Q2 25 | 32.3% | -25.3% | ||
| Q1 25 | 31.4% | -31.0% | ||
| Q4 24 | 35.2% | 12.1% | ||
| Q3 24 | 32.2% | -16.3% | ||
| Q2 24 | 13.5% | -22.6% | ||
| Q1 24 | 25.2% | -80.1% |
| Q4 25 | $0.88 | $-0.04 | ||
| Q3 25 | $0.36 | $-0.09 | ||
| Q2 25 | $0.77 | $-0.16 | ||
| Q1 25 | $0.68 | $-0.18 | ||
| Q4 24 | $0.68 | $0.10 | ||
| Q3 24 | $0.65 | $-0.12 | ||
| Q2 24 | $0.26 | $-0.17 | ||
| Q1 24 | $0.47 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | $184.4M | $31.9M |
| Total Assets | $2.1B | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $259.0M | $24.1M | ||
| Q3 25 | $272.4M | $24.9M | ||
| Q2 25 | $275.7M | $20.3M | ||
| Q1 25 | $241.0M | $21.1M | ||
| Q4 24 | $235.3M | $20.3M | ||
| Q3 24 | $233.5M | $22.5M | ||
| Q2 24 | $241.8M | $23.9M | ||
| Q1 24 | $236.9M | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $184.4M | $31.9M | ||
| Q3 25 | $179.3M | $25.9M | ||
| Q2 25 | $177.0M | $19.2M | ||
| Q1 25 | $172.7M | $21.5M | ||
| Q4 24 | $168.4M | $20.1M | ||
| Q3 24 | $164.0M | $10.9M | ||
| Q2 24 | $159.6M | $11.3M | ||
| Q1 24 | $158.0M | $13.0M |
| Q4 25 | $2.1B | $94.6M | ||
| Q3 25 | $2.1B | $85.2M | ||
| Q2 25 | $2.1B | $81.2M | ||
| Q1 25 | $2.1B | $85.0M | ||
| Q4 24 | $2.1B | $80.2M | ||
| Q3 24 | $2.1B | $64.0M | ||
| Q2 24 | $2.0B | $65.2M | ||
| Q1 24 | $2.0B | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.7M | $-6.3M |
| Free Cash FlowOCF − Capex | $18.2M | — |
| FCF MarginFCF / Revenue | 115.6% | — |
| Capex IntensityCapex / Revenue | 3.1% | — |
| Cash ConversionOCF / Net Profit | 3.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $33.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.7M | $-6.3M | ||
| Q3 25 | $5.5M | $-2.4M | ||
| Q2 25 | $8.0M | $-942.0K | ||
| Q1 25 | $2.2M | $-2.8M | ||
| Q4 24 | $14.2M | $2.2M | ||
| Q3 24 | $-1.3M | $-1.2M | ||
| Q2 24 | $4.0M | $-5.2M | ||
| Q1 24 | $-1.2M | $-5.0M |
| Q4 25 | $18.2M | — | ||
| Q3 25 | $5.2M | — | ||
| Q2 25 | $7.8M | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $13.9M | — | ||
| Q3 24 | $-1.3M | — | ||
| Q2 24 | $4.0M | — | ||
| Q1 24 | $-1.2M | — |
| Q4 25 | 115.6% | — | ||
| Q3 25 | 33.6% | — | ||
| Q2 25 | 50.3% | — | ||
| Q1 25 | 15.2% | — | ||
| Q4 24 | 99.6% | — | ||
| Q3 24 | -9.9% | — | ||
| Q2 24 | 31.6% | — | ||
| Q1 24 | -9.5% | — |
| Q4 25 | 3.1% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 3.26× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 3.21× | 1.46× | ||
| Q3 24 | -0.30× | — | ||
| Q2 24 | 2.35× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CFBK
Segment breakdown not available.
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
